GNS Healthcare discovers which patients respond to drugs and why.

GNS Healthcare accelerates the discovery and development of drugs to improve patient outcomes and significantly reduce total cost of patient care. Our causal AI technology integrates and transforms a wide variety of patient data types into in silico patients which reveal the complex system of interactions underlying disease progression and drug response. The in silico patients enable the simulation of drug response at the individual patient level across oncology, auto-immune, neurology, and cardio-metabolic disease in partnership with the world’s largest biopharma companies and health plans.

How GNS Partners with Pharma and Payers

Novel Simulation for  Discovery and Translational Research

Run in silico simulations to determine intervention effects as well as reveal biomarkers of disease progression and drug response. 

Faster, Better Designed Clinical Trials

Select optimal patient subpopulations for drugs and targets in development. Discover and evaluate the most promising hypotheses before study design, reducing expensive trial and error.


Accelerated Market Access 

Generate evidence of comparative effectiveness at later stages of drug development to support value-based contracts, support line of therapy positioning and label expansion.

Advanced Payer Analytics

Apply AI-drive models across lines of business to better predict rising patient risk and understand which patients are least likely to benefit from interventions or treatments.

Latest from GNS

GNS Healthcare presents novel use of AI to identify drivers of response to immune checkpoint inhibitor therapy.

The Science Behind the Success

Our AI approach has been shown to be the most powerful tool for treatment effectiveness simulation on an individual patient basis. Based on decades of breakthrough academic research, our in silico patients have been validated through over 50 peer-reviewed publications including in top-tier journals such as Lancet Neurology, Leukemia, and PLoS.

The REFS™ Platform

The enabling technology behind GNS partners’ success is our patented REFS platform, the industry’s only platform that can go beyond predicting what may happen – to yield the deeper causal insight into why something happens. The REFS platform has been refined over decades of development and validation, transform data into causal models that deliver insights rapidly and accurately.

Our Partners